Trend > News > Breakingviews – Pfizer’s $43 bln deal is a pricey pipeline fix
Breakingviews – Pfizer’s  bln deal is a pricey pipeline fix
Breakingviews - Pfizer’s $43 bln deal is a pricey pipeline fix,Pfizer has found a partial, costly replacement for waning sales of Covid-19 vaccines. The $225 billion pharmaceutical giant said Monday it had agreed to shell out $43 billion for oncology specialist Seagen , inclusive of net debt. Snag is, Pfizer’s return will probably be low, and the deal may not even receive antitrust approval.

Breakingviews – Pfizer’s $43 bln deal is a pricey pipeline fix

Pfizer has found a partial, costly replacement for waning sales of Covid-19 vaccines. The $225 billion pharmaceutical giant said Monday it had agreed to shell out $43 billion for oncology specialist Seagen , inclusive of net debt. Snag is, Pfizer’s return will probably be low, and the deal may not even receive antitrust approval.